- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07822477
A Study to Investigate Safety, Tolerability and Pharmacokinetics of VH5356136 in Adult Participants Without HIV
A Phase 1, Double-Blind (Sponsor-Unblinded), Placebo-Controlled, Randomized, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Parenterally Administered VH5356136 in Adult Participants Without HIV
Studieoversikt
Status
Forhold
Studietype
Registrering (Antatt)
Fase
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: US GSK Clinical Trials Call Center
- Telefonnummer: 877-379-3718
- E-post: GSKClinicalSupportHD@gsk.com
Studer Kontakt Backup
- Navn: EU GSK Clinical Trials Call Center
- Telefonnummer: +44 (0) 20 89904466
- E-post: GSKClinicalSupportHD@gsk.com
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Participants must be 18 to 55 years of age inclusive at the time of signing the informed consent form (ICF).
- Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
- Participants who are able to understand and comply with protocol requirements and timetables, instructions, and protocol-stated restrictions.
- Body weight ≥50.0 kg (110 lbs) for men and ≥45.0 kg (99 lbs) for women and body mass index within the range 18.5 to 32.0 kg/m^2 (inclusive).
- Participants of any sex (male or female) are eligible. A female participant (female sex assigned at birth) is eligible to participate if they are a person of non-childbearing potential (PONCBP).
- Capable of providing signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in the protocol.
The criteria presented above represent a subset of the key inclusion criteria for the study. Additional criteria, restrictions, and eligibility requirements may apply as specified in the study protocol.
Exclusion Criteria:
- History or presence of, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data.
- History of drug hypersensitivity, delayed-type hypersensitivity or severe hypersensitivity reaction or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates study participation.
- History of or on-going high-risk behaviors that may put the participant at increased risk for HIV acquisition in the opinion of the investigator.
- Any preexisting physical or mental condition which, in the opinion of the investigator or the medical monitor, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant.
- Previous exposure to the parent molecule VH4524184.
- Past or intended use of over-the-counter or prescription medication within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to dosing and for the duration of the study.
- Exposure to an experimental drug or experimental vaccine within either 28 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of study intervention.
- Participants receiving any protocol-prohibited medication and who are unwilling or unable to switch to an alternate medication.
- Current enrolment or participation in another clinical study.
- Any acute laboratory abnormality at screening, which, in the opinion of the investigator, would preclude the participant's participation in the study of an investigational compound.
- Positive HIV antibody/antigen test.
- History of clinically relevant hepatitis within the last 6 months.
- Positive hepatitis B or hepatitis C test.
- Clinically significant cardiovascular disease..
- QT interval corrected for heart rate according to Fridericia's formula (QTcF) >450 milliseconds (msec) and >480 msec (bundle branch block).
- Blood pressure (BP) >140/90 (systolic BP/diastolic BP [SBP/DBP]).
- Resting heart rate (HR) <50 or >100 beats per minute (bpm) when vital signs are measured at Screening or Check-in.
The criteria presented above represent a subset of the key exclusion criteria for the study. Additional criteria, restrictions, and eligibility requirements may apply as specified in the study protocol.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: VH5356136 Formulation 1
Participants will receive a single dose of VH5356136 Formulation 1 administered on Day 1.
|
Participants will receive VH5356136 Formulation 1 on Day 1.
|
|
Placebo komparator: Placebo for VH5356136 Formulation 1
Participants will receive a single dose of placebo for VH5356136 Formulation 1 administered on Day 1.
|
Participants will receive placebo for VH5356136 Formulation 1 on Day 1.
|
|
Eksperimentell: VH5356136 Formulation 2
Participants will receive a single dose of VH5356136 Formulation 2 administered on Day 1.
|
Participants will receive VH5356136 Formulation 2 on Day 1.
|
|
Placebo komparator: Placebo for VH5356136 Formulation 2
Participants will receive a single dose of placebo for VH5356136 Formulation 2 administered on Day 1.
|
Participants will receive placebo for VH5356136 Formulation 2 on Day 1.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of participants with drug-related adverse events (AEs)
Tidsramme: From Day 1 to Month 18
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.
A drug-related AE is an AE that, in the opinion of the investigator, is related to one of the study interventions.
|
From Day 1 to Month 18
|
|
Number of participants with Grade 2 to Grade 5 AEs
Tidsramme: From Day 1 to Month 18
|
The grading of AEs is performed based on the Division of Acquired Immunodeficiency Syndrome (DAIDS) grading scale, here Grade 2 = moderate, Grade 3=severe, Grade 4 = potentially life-threatening, Grade 5 = death.
|
From Day 1 to Month 18
|
|
Number of participants with serious adverse events (SAEs)
Tidsramme: From Day 1 to Month 18
|
An SAE is defined as any untoward medical occurrence that results in death, are life threatening, require hospitalization or prolongation of hospitalization or results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, is considered or defined as an important medical event, or abnormal pregnancy outcomes.
|
From Day 1 to Month 18
|
|
Area under the concentration time curve from zero (pre-dose) to the last quantifiable concentration (post dose) (AUC[0-tlast]) for VH5356136
Tidsramme: From Day 1 (pre-dose) up to Month 18 post-dose
|
From Day 1 (pre-dose) up to Month 18 post-dose
|
|
|
AUC(0-tlast) for VH4524184
Tidsramme: From Day 1 (pre-dose) up to Month 18 post-dose
|
From Day 1 (pre-dose) up to Month 18 post-dose
|
|
|
Maximum plasma concentration (Cmax) for VH5356136
Tidsramme: From Day 1 (pre-dose) up to Month 18 post-dose
|
From Day 1 (pre-dose) up to Month 18 post-dose
|
|
|
Cmax for VH4524184
Tidsramme: From Day 1 (pre-dose) up to Month 18 post-dose
|
From Day 1 (pre-dose) up to Month 18 post-dose
|
|
|
Time to maximum observed plasma drug concentration (tmax) for VH5356136
Tidsramme: From Day 1 (pre-dose) up to Month 18 post-dose
|
From Day 1 (pre-dose) up to Month 18 post-dose
|
|
|
Tmax for VH4524184
Tidsramme: From Day 1 (pre-dose) up to Month 18 post-dose
|
From Day 1 (pre-dose) up to Month 18 post-dose
|
|
|
Terminal half-life (t1/2) for VH5356136
Tidsramme: From Day 1 (pre-dose) up to Month 18 post-dose
|
From Day 1 (pre-dose) up to Month 18 post-dose
|
|
|
t1/2 for VH4524184
Tidsramme: From Day 1 (pre-dose) up to Month 18 post-dose
|
From Day 1 (pre-dose) up to Month 18 post-dose
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of participants with Grade 3 and Grade 4 laboratory abnormalities
Tidsramme: From Day 1 (pre-dose) up to Month 18 post-dose
|
The laboratory abnormalities are assessed using the DAIDS grading scale, where Grade 3 = severe and Grade 4 = potentially life-threatening.
|
From Day 1 (pre-dose) up to Month 18 post-dose
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Blodbårne infeksjoner
- Urogenitale sykdommer
- Kjønnssykdommer
- Sykdommer i immunsystemet
- Infeksjoner
- RNA-virusinfeksjoner
- Virussykdommer
- Smittsomme sykdommer
- Seksuelt overførbare sykdommer, virale
- Seksuelt overførbare sykdommer
- Lentivirus infeksjoner
- Retroviridae-infeksjoner
- Immunologiske mangelsyndromer
- HIV-infeksjoner
Andre studie-ID-numre
- 300862
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
IPD-delingstidsramme
Tilgangskriterier for IPD-deling
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
- SEVJE
- ICF
- CSR
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .